

Marketplace Pharm is a subsidiary of Bristol-Myers Squibb

Interleukin-6 (IL-6) is a pro-inflammatory cytokine produced by a variety of cell types. Kevzara is indicated for the treatment of adult patients with Rheumatoid Arthritis (RA) who have had an inadequate response to one or more disease-modifying antirheumatic drugs (DMARDs). Kevzara may be used in combination with methotrexate (MTX) or other conventional DMARDs. In 2023, Kevzara was also approved for the treatment of adult patients with polymyositis (PM) and dermatomyositis (DM).

Appendix: Preferred Biologic Products

-
-
-

	•
--	---